WATER II (80-150 mL) procedural outcomes.
Ablation Techniques
/ adverse effects
Adenoma
/ surgery
Aged
Endosonography
Hemostasis, Surgical
/ methods
Humans
Length of Stay
Male
Middle Aged
Operative Time
Organ Size
Postoperative Hemorrhage
/ etiology
Prospective Studies
Prostate
/ pathology
Prostatic Hyperplasia
/ complications
Prostatic Neoplasms
/ surgery
Prostatism
/ etiology
Severity of Illness Index
Surveys and Questionnaires
Water
aquablation
benign prostatic hyperplasia
large prostates
robotics
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
pubmed:
26
4
2018
medline:
21
8
2019
entrez:
26
4
2018
Statut:
ppublish
Résumé
To present early safety and feasibility data from a multicentre prospective study (WATER II) of aquablation in the treatment of symptomatic men with large-volume benign prostatic hyperplasia (BPH). Between September and December 2017, 101 men with moderate-to-severe BPH symptoms and prostate volume of 80-150 mL underwent aquablation in a prospective multicentre international clinical trial. Baseline demographics and standardized postoperative management variables were carefully recorded in a central independently monitored database. Surgeons answered analogue scale questionnaires on intra-operative technical factors and postoperative management. Adverse events up to 1 month were adjudicated by an independent clinical events committee. The mean (range) prostate volume was 107 (80-150) mL. The mean (range) operating time was 37 (15-97) min and aquablation resection time was 8 (3-15) min. Adequate adenoma resection was achieved with a single pass in 34 patients and with additional passes in 67 patients (mean 1.8 treatment passes), all in a single operating session. Haemostasis was achieved using either a Foley balloon catheter placed in the bladder under traction (n = 98, mean duration 18 h) or direct tamponade using a balloon inflated in the prostate fossa (n = 3, mean duration 15 h). No patient required electrocautery for haemostasis at the time of the primary procedure. The mean length of stay after the procedure was 1.6 days (range same day to 6 days). The Clavien-Dindo grade ≥2 event rate observed at 1 month was 29.7%. Bleeding complications were recorded in 10 patients (9.9%) during the index procedure hospitalization prior to discharge, and included six (5.9%) peri-operative transfusions. Aquablation is feasible and safe in treating men with men with large prostates (80-150 mL). The 6-month efficacy data are being accrued and will be presented in future publications (ClinicalTrials.gov number, NCT03123250).
Substances chimiques
Water
059QF0KO0R
Banques de données
ClinicalTrials.gov
['NCT03123250']
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Pagination
106-112Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2018 The Authors BJU International © 2018 BJU International Published by John Wiley & Sons Ltd.